Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Insulet Corp (NQ: PODD ) 205.15 +0.73 (+0.36%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Insulet Corp < Previous 1 2 3 4 Next > Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes August 26, 2024 From Insulet Corporation Via Business Wire Insulet to Present at Upcoming Investor Conferences August 20, 2024 From Insulet Corporation Via Business Wire Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia August 14, 2024 From Insulet Corporation Via Business Wire Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year August 08, 2024 From Insulet Corporation Via Business Wire Insulet Reports Preliminary Second Quarter 2024 Revenue Results July 26, 2024 From Insulet Corporation Via Business Wire Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024 July 08, 2024 From Insulet Corporation Via Business Wire Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes June 21, 2024 From Insulet Corporation Via Business Wire Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands June 20, 2024 From Insulet Corporation Via Business Wire Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates June 20, 2024 From Insulet Corporation Via Business Wire Insulet to Present at the Jefferies Global Healthcare Conference May 28, 2024 From Insulet Corporation Via Business Wire Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year May 09, 2024 From Insulet Corporation Via Business Wire Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth May 07, 2024 From Insulet Corporation Via Business Wire Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 April 03, 2024 From Insulet Corporation Via Business Wire Insulet Appoints Ana Maria Chadwick as Chief Financial Officer March 20, 2024 From Insulet Corporation Via Business Wire Are These 5 Undervalued Stocks Ready to Break Out? March 08, 2024 Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. Via MarketBeat Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy March 08, 2024 From Insulet Corporation Via Business Wire Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) March 05, 2024 From Insulet Corporation Via Business Wire Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency) February 22, 2024 From Insulet Corporation Via Business Wire Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference February 13, 2024 From Insulet Corporation Via Business Wire Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor February 07, 2024 From Insulet Corporation Via Business Wire 5 top healthcare stocks for earnings growth in 2024 January 25, 2024 2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. Via MarketBeat MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs January 22, 2024 With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs. Via MarketBeat Topics Earnings Exposures Financial Insulet Announces Changes to Board of Directors with Retirements and New Appointments January 18, 2024 From Insulet Corporation Via Business Wire Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 January 11, 2024 From Insulet Corporation Via Business Wire HCA Healthcare Rallies: Weight-loss drugs really a big threat? January 08, 2024 HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. Via MarketBeat Topics ETFs Insulet to Present at Upcoming Investor Conferences November 28, 2023 From Insulet Corporation Via Business Wire Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029 November 17, 2023 EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 Wall Street sees these 2023 losers as 2024 opportunities November 09, 2023 Analysts are pointing at undervalued, oversold companies like these three S&P 500 laggards as potential investment opportunities heading into 2024. Via MarketBeat Topics Stocks Exposures US Equities Large cap earnings trade ideas for risk-seeking investors November 07, 2023 Positive earnings surprises (and the magnitude of surprises) are above historical norms as of late - and these three stocks could keep the party going. Via MarketBeat Topics Economy Exposures Interest Rates Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency1) November 02, 2023 From Insulet Corporation Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.